The Significant Antitumor Activity of Nivolumab in Lung Adenocarcinoma with Choriocarcinomatous Features

Intern Med. 2018 Jun 15;57(12):1773-1777. doi: 10.2169/internalmedicine.0002-17. Epub 2018 Feb 9.

Abstract

We report the case of a 60-year-old Japanese man with a metastatic brain tumor that caused ataxia. As a consequence of resection of a cerebellar tumor, the tumor was diagnosed as a poorly differentiated adenocarcinoma with choriocarcinomatous features. The patient underwent bronchoscopy, leading to a diagnosis of the same histology as the brain tumor. After the administration of first-line chemotherapy and maintenance therapy due to progressive disease, he was given nivolumab and obtained a partial response; however, 11-months later, computed tomography showed tumor progression. Our experience suggests that nivolumab has strong activity, even in patients with a rare form of lung cancer.

Keywords: PD-1; PD-L1; acquisition of resistance; choriocarcinoma; nivolumab.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / secondary
  • Adenocarcinoma of Lung
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use
  • Brain Neoplasms / pathology*
  • Choriocarcinoma / pathology*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary
  • Male
  • Middle Aged
  • Nivolumab
  • Tomography, X-Ray Computed

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Nivolumab